Sinovac Graham Net Net from 2010 to 2026
| SVA Stock | USD 6.47 0.00 0.00% |
Graham Net Net | First Reported 2010-12-31 | Previous Quarter 90.32 | Current Value 94.83 | Quarterly Volatility 49.30422692 |
Check Sinovac Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinovac Biotech's main balance sheet or income statement drivers, such as Interest Expense of 2.7 M, Other Operating Expenses of 1.2 B or Total Operating Expenses of 982.3 M, as well as many indicators such as Price To Sales Ratio of 1.57, Dividend Yield of 0.51 or PTB Ratio of 0.0808. Sinovac financial statements analysis is a perfect complement when working with Sinovac Biotech Valuation or Volatility modules.
Sinovac | Graham Net Net | Build AI portfolio with Sinovac Stock |
Analyzing Sinovac Biotech's Graham Net Net over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Graham Net Net has evolved provides context for assessing Sinovac Biotech's current valuation and future prospects.
Latest Sinovac Biotech's Graham Net Net Growth Pattern
Below is the plot of the Graham Net Net of Sinovac Biotech over the last few years. It is Sinovac Biotech's Graham Net Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sinovac Biotech's overall financial position and show how it may be relating to other accounts over time.
| Graham Net Net | 10 Years Trend |
|
Graham Net Net |
| Timeline |
Sinovac Graham Net Net Regression Statistics
| Arithmetic Mean | 36.61 | |
| Geometric Mean | 3.93 | |
| Coefficient Of Variation | 134.68 | |
| Mean Deviation | 45.48 | |
| Median | 2.13 | |
| Standard Deviation | 49.30 | |
| Sample Variance | 2,431 | |
| Range | 115 | |
| R-Value | 0.82 | |
| Mean Square Error | 861.05 | |
| R-Squared | 0.67 | |
| Significance | 0.000062 | |
| Slope | 7.98 | |
| Total Sum of Squares | 38,895 |
Sinovac Graham Net Net History
About Sinovac Biotech Financial Statements
Sinovac Biotech stakeholders use historical fundamental indicators, such as Sinovac Biotech's Graham Net Net, to determine how well the company is positioned to perform in the future. Although Sinovac Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sinovac Biotech's assets and liabilities are reflected in the revenues and expenses on Sinovac Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sinovac Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Graham Net Net | 90.32 | 94.83 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sinovac Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sinovac Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sinovac Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sinovac Biotech Stock:Check out the analysis of Sinovac Biotech Correlation against competitors. For information on how to trade Sinovac Stock refer to our How to Trade Sinovac Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sinovac Biotech. If investors know Sinovac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sinovac Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 3.548 | Earnings Share 0.971 | Revenue Per Share | Quarterly Revenue Growth 3.037 | Return On Assets |
Understanding Sinovac Biotech requires distinguishing between market price and book value, where the latter reflects Sinovac's accounting equity. The concept of intrinsic value - what Sinovac Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Sinovac Biotech's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sinovac Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sinovac Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sinovac Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.